See more : Vision Airships Inc. (VPSN) Income Statement Analysis – Financial Results
Complete financial analysis of Abeona Therapeutics Inc. (ABEO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Abeona Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SportsTek Acquisition Corp. (SPTKU) Income Statement Analysis – Financial Results
- Ritco Logistics Limited (RITCO.NS) Income Statement Analysis – Financial Results
- Nuheara Limited (NUHRF) Income Statement Analysis – Financial Results
- Muhibbah Engineering (M) Bhd. (5703.KL) Income Statement Analysis – Financial Results
- Advanced Power Electronics Co., Ltd. (8261.TW) Income Statement Analysis – Financial Results
Abeona Therapeutics Inc. (ABEO)
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.50M | 1.41M | 3.00M | 10.00M | 0.00 | 3.00M | 837.00K | 889.00K | 1.04M | 925.00K | 2.04M | 4.40M | 1.85M | 481.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 549.00K | 1.30M | 1.15M | 243.00K | 107.00K | 15.00K | 100.00K | 435.00K | 167.00K | 2.95M |
| Cost of Revenue | 1.61M | 450.00K | 4.46M | 30.14M | 8.68M | 38.70M | 16.99M | 10.66M | 0.00 | 0.00 | 125.00K | 267.00K | 1.22M | 140.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 239.00K | 277.00K | 107.00K | 0.00 | 0.00 | 0.00 | 0.00 | 580.00K | 8.31M | 0.00 |
| Gross Profit | 1.90M | 964.00K | -1.46M | -20.14M | -8.68M | -35.70M | -16.15M | -9.77M | 1.04M | 925.00K | 1.92M | 4.14M | 632.00K | 341.00K | 352.00K | 291.00K | 57.00K | 0.00 | 0.00 | 310.00K | 1.02M | 1.04M | 243.00K | 107.00K | 15.00K | 100.00K | -145.00K | -8.15M | 2.95M |
| Gross Profit Ratio | 54.14% | 68.18% | -48.80% | -201.39% | 0.00% | -1,190.79% | -1,929.75% | -1,098.54% | 100.00% | 100.00% | 93.88% | 93.94% | 34.20% | 70.89% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 56.47% | 78.61% | 90.67% | 100.00% | 100.00% | 100.00% | 100.00% | -33.33% | -4,878.44% | 100.00% |
| Research & Development | 31.09M | 28.97M | 34.33M | 30.14M | 48.57M | 38.70M | 16.99M | 10.66M | 4.72M | 333.00K | 884.00K | 2.01M | 4.20M | 3.35M | 2.66M | 12.61M | 2.60M | 2.05M | 2.78M | 5.42M | 6.10M | 7.02M | 4.17M | 4.01M | 1.61M | 1.80M | 2.43M | 1.41M | 1.25M |
| General & Administrative | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 0.00 | 6.02M | 583.00K | 4.51M | 7.11M | 4.34M | 957.00K | 0.00 | 4.64B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.49M | 0.00 | 0.00 | 0.00 | 3.12M | 0.00 | -4.63B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.00M | 17.26M | 22.80M | 23.78M | 20.71M | 20.11M | 10.94M | 13.29M | 14.32M | 3.71M | 4.83M | 6.02M | 4.08M | 4.51M | 7.11M | 4.34M | 4.08M | 2.81M | 4.64M | 3.20M | 2.51M | 2.28M | 1.96M | 1.74M | 1.47M | 1.50M | 1.78M | 1.94M | 1.35M |
| Other Expenses | 0.00 | 141.00K | 3.25M | 4.59M | 7.82M | 2.36M | 741.00K | 825.00K | 551.00K | 3.72M | 4.84M | 419.00K | 4.31M | 238.00K | 259.00K | 253.00K | 4.36M | 3.12M | 6.84M | 3.97M | 3.14M | 2.72M | 2.38M | 2.16M | 1.76M | 1.70M | 1.95M | 2.06M | 1.35M |
| Operating Expenses | 49.03M | 46.22M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.72M | 8.45M | 8.51M | 8.10M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.39M | 9.23M | 9.74M | 6.55M | 6.17M | 3.36M | 3.50M | 4.38M | 3.47M | 2.60M |
| Cost & Expenses | 50.64M | 46.67M | 60.37M | 58.50M | 77.09M | 61.16M | 28.67M | 24.77M | 19.59M | 4.06M | 5.85M | 8.72M | 9.72M | 8.24M | 10.03M | 17.21M | 6.96M | 5.18M | 9.62M | 9.63M | 9.51M | 9.85M | 6.55M | 6.17M | 3.36M | 3.50M | 4.96M | 11.78M | 2.60M |
| Interest Income | 2.12M | 431.00K | 69.00K | 1.30M | 1.21M | 1.51M | 525.00K | 2.01M | 4.03M | 45.00K | 251.00K | 242.00K | 1.33M | 2.05M | 29.00K | 178.00K | 125.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 418.00K | 736.00K | 3.67M | 4.12M | 400.00K | 11.00K | 8.00K | 6.00K | 6.00K | 582.00K | 279.00K | 608.00K | 963.00K | 607.00K | 539.00K | 478.00K | 3.51M | 7.44M | 2.10M | 1.39M | 1.28M | 1.28M | 1.17M | 342.00K | 0.00 | 0.00 | 0.00 | 45.00K | 0.00 |
| Depreciation & Amortization | 3.20M | 4.58M | 4.46M | 5.60M | 8.68M | 2.36M | 741.00K | 825.00K | 551.00K | 11.00K | 3.00K | 419.00K | 233.00K | 238.00K | 259.00K | 253.00K | 2.60M | 7.06M | 1.57M | 1.08M | 898.00K | 686.00K | 627.00K | 476.00K | 285.00K | 200.00K | 162.00K | 123.00K | 15.00K |
| EBITDA | -50.57M | -34.38M | -76.80M | -74.52M | -67.61M | -54.31M | -26.58M | -21.05M | -13.97M | -26.19M | 4.73M | -9.51M | -1.32M | -6.69M | -16.54M | -16.48M | -18.12M | 2.99M | -7.56M | -4.93M | -4.53M | -8.01M | -5.68M | -5.58M | -3.06M | -3.30M | -4.36M | -11.49M | 356.00K |
| EBITDA Ratio | -1,444.91% | -3,160.18% | -1,801.70% | -426.17% | 0.00% | -1,811.21% | -3,174.43% | -2,366.93% | -1,343.17% | -332.43% | -173.85% | -82.99% | -341.40% | -1,309.77% | -642.90% | -5,664.60% | 12,847.37% | 0.00% | 0.00% | -1,457.74% | -564.86% | -698.69% | -2,337.86% | -5,216.82% | -20,426.67% | -3,200.00% | -1,030.11% | -6,997.60% | 12.09% |
| Operating Income | -47.14M | -45.26M | -89.84M | -81.42M | -77.09M | -58.17M | -27.84M | -23.88M | -18.55M | -3.13M | -3.80M | -4.32M | -7.88M | -7.76M | -9.68M | -16.92M | -6.90M | -5.18M | -9.62M | -9.08M | -8.21M | -8.70M | -6.31M | -6.06M | -3.35M | -3.40M | -4.52M | -11.61M | 341.00K |
| Operating Income Ratio | -1,346.71% | -3,200.64% | -2,994.53% | -814.20% | 0.00% | -1,940.16% | -3,325.69% | -2,686.28% | -1,783.27% | -338.49% | -186.29% | -98.00% | -426.19% | -1,612.68% | -2,748.86% | -5,812.71% | -12,105.26% | 0.00% | 0.00% | -1,653.73% | -634.21% | -758.50% | -2,595.88% | -5,661.68% | -22,326.67% | -3,400.00% | -1,040.00% | -6,953.89% | 11.58% |
| Total Other Income/Expenses | -7.05M | 11.22M | 4.90M | -2.81M | 808.00K | 1.50M | 517.00K | 2.01M | 4.02M | -23.65M | 8.25M | -6.22M | 5.36M | 220.00K | -7.15M | -300.00K | -15.02M | -8.25M | -4.07M | -1.16M | 1.79M | -684.00K | 281.00K | 630.00K | 41.00K | 0.00 | 83.00K | 151.00K | 0.00 |
| Income Before Tax | -54.19M | -39.70M | -84.94M | -84.23M | -76.28M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.52M | -8.98M | -16.83M | -17.22M | -21.92M | 13.42M | -11.62M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | 0.00 | -4.44M | -11.46M | 341.00K |
| Income Before Tax Ratio | -1,548.23% | -2,807.36% | -2,831.20% | -842.34% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -136.09% | -1,866.11% | -4,781.25% | -5,915.81% | -38,450.88% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | 0.00% | -1,020.92% | -6,863.47% | 11.58% |
| Income Tax Expense | 0.00 | -7.89M | 3.67M | 4.12M | 400.00K | 1.51M | 525.00K | 2.01M | 4.03M | 582.00K | 279.00K | 608.00K | 17.00K | -220.00K | 7.66M | 178.00K | -61.00K | -173.00K | -4.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -83.00K | -151.00K | 0.00 |
| Net Income | -54.19M | -31.81M | -88.61M | -88.35M | -76.68M | -56.67M | -27.32M | -21.87M | -14.53M | -26.78M | 4.45M | -10.53M | -2.53M | -7.54M | -17.34M | -17.22M | -21.86M | -12.87M | -1.70M | -10.24M | -6.94M | -9.38M | -6.03M | -5.43M | -3.31M | -3.40M | -4.44M | -11.46M | 341.00K |
| Net Income Ratio | -1,548.23% | -2,249.58% | -2,953.53% | -883.49% | 0.00% | -1,890.29% | -3,263.92% | -2,460.40% | -1,396.73% | -2,894.92% | 217.87% | -239.15% | -137.01% | -1,566.94% | -4,926.14% | -5,915.81% | -38,343.86% | 0.00% | 0.00% | -1,864.85% | -535.52% | -818.13% | -2,480.25% | -5,072.90% | -22,053.33% | -3,400.00% | -1,020.92% | -6,863.47% | 11.58% |
| EPS | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.75 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| EPS Diluted | -2.53 | -4.05 | -22.50 | -23.84 | -38.07 | -29.81 | -16.40 | -16.00 | -13.16 | -344.56 | 76.00 | -544.49 | -158.39 | -602.67 | -1.83K | -2.58K | -7.69K | -4.56K | -656.62 | -4.22K | -3.27K | -4.48K | -2.93K | -3.07K | -3.40K | -6.20K | -317.21K | -955.17K | 37.89K |
| Weighted Avg Shares Out | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.19K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
| Weighted Avg Shares Out (Dil) | 21.38M | 7.86M | 3.94M | 3.71M | 2.01M | 1.90M | 1.67M | 1.37M | 1.10M | 77.72K | 20.38K | 19.34K | 15.99K | 12.51K | 9.45K | 6.68K | 2.84K | 2.83K | 2.59K | 2.43K | 2.12K | 2.10K | 2.06K | 1.77K | 974.00 | 548.00 | 14.00 | 12.00 | 9.00 |
Best Penny Stocks To Buy Now? 4 Biotech Stocks To Watch
Best penny stocks to buy? Biotech penny stocks are heating up & these 4 might be worth watching now.
Abeona Therapeutics Announces Completion of Patient Follow-up in Pivotal Phase 3 VIITAL™ Study of EB-101 in Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Topline VIITAL™ study results expected within the next month Topline VIITAL™ study results expected within the next month
Abeona Therapeutics to Participate in the Jefferies Cell and Genetic Medicine Summit
NEW YORK and CLEVELAND, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a fireside chat at the Jefferies Cell and Genetic Medicine Summit on...
Abeona Therapeutics to Participate in the Cantor Fitzgerald Cell and Genetic Medicines Conference
NEW YORK and CLEVELAND, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Vish Seshadri, Chief Executive Officer of Abeona, will participate in a panel discussion at the Cantor Fitzgerald Cell and Genetic Medicines Conference...
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023
Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with...
Abeona Therapeutics to Present at the Jefferies Healthcare Conference
NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June...
Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq's Listing Qualification Department,...
Abeona Therapeutics (ABEO) CEO, Vishwas Seshadri on Q1 2022 Results - Earnings Call Transcript
Abeona Therapeutics Inc. (NASDAQ:ABEO ) Q1 2022 Earnings Conference Call May 17, 2022 8:30 AM ET Company Participants Vishwas Seshadri - Chief Executive Officer Joseph Vazzano - Chief Financial Officer Brian Kevany - Chief Technical Officer, Head of Research Greg...
Abeona Therapeutics Reports First Quarter 2022 Financial Results
Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023
Source: https://incomestatements.info
Category: Stock Reports